Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Chronic Cannabidiol Treatment in the Rat Chronic Unpredictable Mild Stress Model of Depression
Zsolt Gáll, Szidónia Farkas, Ákos Albert, et al.
Biomolecules (2020) Vol. 10, Iss. 5, pp. 801-801
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
María S. García‐Gutiérrez, Francisco Navarrete, Ani Gasparyan, et al.
Biomolecules (2020) Vol. 10, Iss. 11, pp. 1575-1575
Open Access | Times Cited: 211
Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study
L. Cinnamon Bidwell, Renée Martin‐Willett, Carillon J. Skrzynski, et al.
Cannabis and Cannabinoid Research (2024) Vol. 9, Iss. 4, pp. 1015-1027
Closed Access | Times Cited: 8
Developmental cannabidiol exposure increases anxiety and modifies genome-wide brain DNA methylation in adult female mice
Nicole M. Wanner, Mathia Colwell, Chelsea Drown, et al.
Clinical Epigenetics (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 50
Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19
Barbara Malinowska, Marta Baranowska‐Kuczko, Aleksandra Kicman, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1986-1986
Open Access | Times Cited: 46
Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence
Uri Bright, Irit Akirav
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5526-5526
Open Access | Times Cited: 29
Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review
Kuldeep Singh, Bharat Bhushan, Dilip Kumar Chanchal, et al.
Behavioural Neurology (2023) Vol. 2023, pp. 1-17
Open Access | Times Cited: 19
Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial
Erin L. Martin, Justin C. Strickland, Nicolas J. Schlienz, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 40
Effects of cannabinoid (CBD) on blood brain barrier permeability after brain injury in rats
Hongyan Jiang, Hengxi Li, Yan Cao, et al.
Brain Research (2021) Vol. 1768, pp. 147586-147586
Closed Access | Times Cited: 35
P2X7 receptors from the perspective of NLRP3 inflammasome pathway in depression: Potential role of cannabidiol
Elif Akçay, Hülya Karataş
Brain Behavior & Immunity - Health (2024) Vol. 41, pp. 100853-100853
Open Access | Times Cited: 5
Facile engineered macrophages-derived exosomes-functionalized PLGA nanocarrier for targeted delivery of dual drug formulation against neuroinflammation by modulation of microglial polarization in a post-stroke depression rat model
Zhongyue Lv, Cui Zhao, Xiping Wu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117263-117263
Open Access | Times Cited: 5
Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
Tibor Štark, Serena Di Martino, Filippo Drago, et al.
Pharmacological Research (2021) Vol. 174, pp. 105938-105938
Closed Access | Times Cited: 32
Neuroprotective Efficiency of Prodigiosins Conjugated with Selenium Nanoparticles in Rats Exposed to Chronic Unpredictable Mild Stress is Mediated Through Antioxidative, Anti-Inflammatory, Anti-Apoptotic, and Neuromodulatory Activities
Ashraf Albrakati, Khalaf F. Alsharif, Naif E. Al omairi, et al.
International Journal of Nanomedicine (2021) Vol. Volume 16, pp. 8447-8464
Open Access | Times Cited: 31
Down and High: Reflections Regarding Depression and Cannabis
Catherine C. Langlois, Stéphane Potvin, Atul Khullar, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 28
Strain-, Sex-, and Time-Dependent Antidepressant-like Effects of Cannabidiol
Gabriela Pandini Silote, Michelle Carvalho Gatto, Amanda Eskelund, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 12, pp. 1269-1269
Open Access | Times Cited: 28
Topical Collection “Pharmacology of Medicinal Plants”
Barbara Romano, Giuseppe Lucariello, Raffaele Capasso
Biomolecules (2021) Vol. 11, Iss. 1, pp. 101-101
Open Access | Times Cited: 27
Effects of Oral Cannabidiol on Health and Fitness in Healthy Adults: An 8-Week Randomized Trial
Victoria Flores, Jacob N. Kisiolek, Arjun Ramani, et al.
Nutrients (2023) Vol. 15, Iss. 12, pp. 2664-2664
Open Access | Times Cited: 11
In Vitro and In Vivo Anti-Inflammatory and Antidepressant-like Effects of Cannabis sativa L. Extracts
Joonyoung Shin, Sangheon Choi, A Yeong Park, et al.
Plants (2024) Vol. 13, Iss. 12, pp. 1619-1619
Open Access | Times Cited: 4
Cannabidiol Modulates Neuroinflammatory and Estrogen-Related Pathways in a Sex-Specific Manner in a Chronic Stress Model of Depression
Uri Bright, Irit Akirav
Cells (2025) Vol. 14, Iss. 2, pp. 99-99
Open Access
Comparison between Cannabidiol and Fluoxetine effects on chronic neuropathic pain and depression comorbid in rats
Daimio C. Brito, Ana Carolina Medeiros, Christie Ramos Andrade Leite‐Panissi, et al.
Neuroscience and Behavioral Physiology (2025)
Closed Access
Co-treatment with cannabidiol and escitalopram in ineffective doses induces antidepressant effect in maternally separated male adolescent rats
Jonasz Dragon, Miłosz Gołyszny, Ewa Obuchowicz
Pharmacology Biochemistry and Behavior (2025), pp. 174000-174000
Closed Access
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool
C. Kwee, Joop MA van Gerven, Fleur L.P. Bongaerts, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 12, pp. 1299-1314
Open Access | Times Cited: 17
Anticonvulsant Action and Long-Term Effects of Chronic Cannabidiol Treatment in the Rat Pentylenetetrazole-Kindling Model of Epilepsy
Zsolt Gáll, Krisztina Kelemen, Andrea Tolokán, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1811-1811
Open Access | Times Cited: 16
Cannabidiol Reduces Short- and Long-Term High Glutamate Release after Severe Traumatic Brain Injury and Improves Functional Recovery
Cindy Santiago-Castañeda, Saúl Huerta de la Cruz, Christopher Martínez-Aguirre, et al.
Pharmaceutics (2022) Vol. 14, Iss. 8, pp. 1609-1609
Open Access | Times Cited: 16
CBD-Loaded Nanostructured Lipid Carriers: Optimization, Characterization, and Stability
Yang Xie, Peng Li, Dong Fu, et al.
ACS Omega (2024) Vol. 9, Iss. 39, pp. 40632-40643
Open Access | Times Cited: 3
In Vitro Effects of Cannabidiol on Activated Immune–Inflammatory Pathways in Major Depressive Patients and Healthy Controls
Muanpetch Rachayon, Ketsupar Jirakran, Pimpayao Sodsai, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 4, pp. 405-405
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top